FDA credibility damaged by AMT-130 rejection
The speakers argued the FDA's rejection of AMT-130, despite strong biomarker and clinical data, severely damages its scientific credibility and suggests it is not consulting Huntington's disease experts.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.